COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma (IPIAP-STM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03514381
Recruitment Status : Active, not recruiting
First Posted : May 2, 2018
Last Update Posted : October 14, 2020
Information provided by (Responsible Party):
Institut Claudius Regaud

Brief Summary:

This trial is a multicentric study aiming to assess the evolution of the serum ifosfamide concentrations and its serum metabolites in patients treated for an Soft Tissue Sarcoma and co-exposed to Aprepitant.

The study will be conducted on a population of patients treated with Doxorubicin and Ifosfamide. The Aprepitant can be prescribed to patients from cycle 2, according to the current recommendations. Doxorubicin, Ifosfamide and Aprepitant will be administered in the context of routine care. The follow-up during the treatment period and the clinical, biological and radiological assessments will be performed according to the standard of each centre.

Patients will be followed during the two first cycles of treatment. For the pharmacokinetic study, blood samples will be collected at different time points during the 2 treatment cycles.

Condition or disease Intervention/treatment Phase
Soft Tissue Sarcoma Drug: Patients starting a treatment with Doxorubicin and Ifosfamide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma
Actual Study Start Date : May 18, 2018
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Patients starting a treatment with Doxorubicin and Ifosfamide Drug: Patients starting a treatment with Doxorubicin and Ifosfamide

9 blood samples will be collected at each Cycle:

  • Cycle 1 (Day 1-Day 2-Day 3)
  • Cycle 2 (Day 1-Day 2-Day 3)

Primary Outcome Measures :
  1. Evolution of 2d-Ifo plasma concentrations between the 1st cycle (without co-exposure to the Aprepitant) and the 2nd cycle (with co-exposure to the Aprepitant) [ Time Frame: Cycle 2 Day 3 for each patient ]

Secondary Outcome Measures :
  1. Toxicity assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 [ Time Frame: Cycle 3 Day 1 for each patient ]
  2. Evolution of plasma concentrations of ifosfamide and its serum metabolites between the first and second cycles [ Time Frame: Cycle 3 Day 1 for each patient ]
  3. The rate of objective responses determined according to the criteria RECIST v 1.1 [ Time Frame: Cycle 3 Day 1 for each patient ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Anatomopathologic diagnosis of soft tissue sarcoma (localized, local recidive or metastatic).
  3. Patient receiving doxorubicin and ifosfamide chemotherapy (treatment decided during Multidisciplinary consultation meetings) (neoadjuvant, adjuvant or palliative treatment).
  4. Screening laboratory values must meet the following criteria:

    1. Hemoglobin > 9.0 g/dL, Neutrophils > 1500/mm3, Platelets > 100000/mm3
    2. Creatinine clearance (MDRD formula) > 60ml/min.
    3. AST/ALT < 2.5 x ULN (5 x ULN in patients with hepatic metastasis).
  5. Evaluable disease (measurable per RECIST or not), if applicable.
  6. Patient must provide written informed consent prior to any study specific procedures.
  7. Patient affiliated to a Social Health Insurance in France.

Exclusion Criteria:

  1. Previous treatment with Ifosfamide.
  2. Patient who has already started doxorubicin and ifosfamide treatment.
  3. Any medical condition that can increase the patient's risk

    1. Active infection
    2. Active hepatitis or cirrhosis
    3. Recipients of organ transplants or immunocompromised patients, including Human Immunodeficiency Virus (HIV) infection
  4. Pregnant or breastfeeding women
  5. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure
  6. Patient protected by law

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03514381

Layout table for location information
Institut Bergonie
Bordeaux, France, 33076
Institut Regional Du Cancer de Montpellier (Icm)
Montpellier, France, 34298
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, France, 31059
Sponsors and Collaborators
Institut Claudius Regaud
Layout table for additonal information
Responsible Party: Institut Claudius Regaud Identifier: NCT03514381    
Other Study ID Numbers: 17 SARC 04
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Claudius Regaud:
Soft Tissue Sarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents